|
|
|
- まいか はにうだ
- 7 years ago
- Views:
Transcription
1
2
3 (Quality of Life; QL) QL (Nerve Growth Factor; NGF) NGF PC12 6- (6-HITC)
4 NGF NGF NGF PTP1B 6-HITC PTP1B NGF PTP1B 6-HITC PTP1B 6-HITC NGF 6-HITC 6-HITC in vivo Tel:
5
6
7 20-Hydroxyecdysone Dibenzoylhydrazine
8
9
10
11 ABA 1960 ABA ABA ABA ABA ABA ABA ABA ABA ABA ABA ABA 8'- P450 ABA ABA
12 ABA ABA ABA 8' TEL&FAX
13
14
15
16 NH PP N R H H HH NH H P P N H H HH R UDP H AcHN H H H H H H H H C - H H AcHN H P P - - AcHN H H H P - NH N HH P - NH N HH UDP-LacNAc Kobata, J. Biochem., 53, 167 (1963). UDP-Neu5AcLacNAc Jourdian et al., Fed. Proc., 20, 161 (1961). UDP j @guedu.cc.gifu-u.ac.jp Tel :
17 Flammulina velutipes F. velutipes PCR fluorescence differential display (FDD) 10 RNA FDD cdna accession No. AB AB northern blot BLASTX 29 cdna GTP-binding protein growth factor ubiqutin-proteasome cytochrome P450 hydrophobin polysaccharide deacetylase
18 Fluorescence Differential Disply
19
20 Wild-type rsp5 mutant YPD 25 YPD 37 SD 37 Ubiquitination Ub Ub Growth No Ubiquitination Growth inhibition Rsp5 Ub Ub Ub Abnormal proteins Degradation in proteasome or vacuole rsp5 Ub Abnormal proteins accumulation Wild-type rsp5 mutant + Temp. up-shift + Sorbitol + Ethanol Wild-type Time min HSP12 ACT1 rsp5 mutant Time min Wild-type rsp5 mutant V H M V H -HA western -Pgk1 western M Hsf1 Msn4 Pgk1 Golgi ER proteasome Ub Ub Rsp5 Ubiquitination? Hsf1 HSE Ub Hsf1 Msn2/4 STRE Ub Msn2/4 Transport? Nucleus Induction HSP42, HSP12, DDR2
21 Figure 1 H 3 S H NH2 R Me N H N NH H 2 C N Me H H 1a: Liposidomycin A : R= Me (CH 2 ) 3 1b: Liposidomycin B : R= 1c: Liposidomycin C : R= CH 2 Me 2 (CH 2 ) 8 Me(CH 2 ) 10 H H 2 C N Me Me N H H N H degradation product (2) NH
22 Figure 2 Me H N H N H 2 C N Me H H 2 NH Me Bz N Bn N Ph N Me Ac Ac 3 NH Ph NH Me 4 + H N 3 5 Bn Me H Bz H Ph N Me H D-ribose Me N 7 H Bn 5 Me (CCl) 2, DIPEA CH 2 Cl 2 4 (11steps 20% from D-ribose) 2 steps 41% Bz Ph Me Ph N Me N N 3 6 Ac 8 Bn Me N Bn Ac Ac Me 7steps 11% TMS N N SnCl 4 9 TMS 3 Figure 3 Bn Ac N Bn 4 steps 9,SnCl 4 N NH N 37% Ns 55% R Ac Ac Ac Ac Bn N Me 10 11: R=Ns 13 12: R=CH Bz R R N Bn N Bn Bz Ac N NH Ph N Ph N Me Ac Ac Me Ac Ac 14 R=Ns or CH 15 N NH 3 2
23 ( TGase TGase 8 TGase 1, 3 Factor XIII TGase 2 TGase TGase TGase M13 piii N 12 TGase
24 TGase TGase 2 Factor XIII TGase N
25
26 - (Caco-2 ) (HepG2 ) I-I-A-E-K ( ) Ile Ile Ala Glu Lys Biochem. Biophys. Res. Commun. 281, (2001)
27 (RAS) (ACE) RAS D R V Y I H P F H L V D R V Y I H P F H L D R V Y I H P F RAS 10 ACE Na His P5 -Pro P4 -Phe P3 (HPF)
28 1) HPF HPF (VA) WSZ1a BSZ4 8 RADHPF( III) ADHPFLFLIK(VA-X ) ADHPFLFFIR(VA-Y ) DHPFLFLV HPFLFLVR(WSZ1a ) VANHPFLFLIRVANHPFLFLIR(BSZ4 ) (TRX)C (TRX- ) BL21(DE3) TRX TRX (300 µm) TRX 100 TRX-ADHPFLFLIKTRX-ADHPFLFFIR TRX-DHPFLFLVTRX-HPFLFLVRTRX-VANHPFLFLIR TRX-ADHPFLFLIKTRX-ADHPFLFFIRTRX-DHPFLFLVTRX-HPFLFLVR TRX-VANHPFLFLIR(300 µm) IC µm TRX-VANHPFLFLIR Ki 53 µm TRX-RADHPFTRX-VANHPFTRX-LFLIR(300 µm) HPF C () () 1) 2002 p. 123
29
30
31 γ [ ] 3 ATP 2 γ GCS γ 2 γ GCS
32 GCS buthionine sulfoximine(bs) BS GCS GCS BS GCS BS X [ ] GCSBSMgADP PEG10,000 X SPring-8 BL40B2 2.3Å P21 a=70.5 Å, b=97.6 Å, c=102.7 Å, β=109.5 R 21%(Rfree24) GCSBSMgADP ATP γ BS BS TSA GCS α TSA Tyr241 Tyr300 GCS GCSTSA BS Tyr300 Tyr300 BS TSA 500 Tyr300 Tyr241 Tyr241 Tyr241 BS CH-π Tyr241 Gln144
3/4/8:9 { } { } β β β α β α β β
α β : α β β α β α, [ ] [ ] V, [ ] α α β [ ] β 3/4/8:9 3/4/8:9 { } { } β β β α β α β β [] β [] β β β β α ( ( ( ( ( ( [ ] [ ] [ β ] [ α β β ] [ α ( β β ] [ α] [ ( β β ] [] α [ β β ] ( / α α [ β β ] [ ] 3
研修コーナー
l l l l l l l l l l l α α β l µ l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
Perl + α. : DNA, mrna,,
2009 Perl + α. : DNA, mrna,, DNA .. DNA A C G T DNA 2 A-T, C-G DNA NH 2 NH 2 O - O O N P O - O CH 2 O N N O - O P O CH 2 O N O - O O P O NH 2 O - O - N CH 2 O N O OH OH OH DNA or RNA (U) (A) (G) (C)
ｎｓｇ０２－１３／ｋｙ０４５０５９３０１６０００３３２１０
φ φ φ φ κ κ α α μ μ α α μ χ et al Neurosci. Res. Trpv J Physiol μ μ α α α β in vivo β β β β β β β β in vitro β γ μ δ μδ δ δ α θ α θ α In Biomechanics at Micro- and Nanoscale Levels, Volume I W W v W
ｎｓｇ０４－２８／ｋｙ２０８６８４３５６１０００４３０７７
δ!!! μ μ μ γ UBE3A Ube3a Ube3a δ !!!! α α α α α α α α α α μ μ α β α β β !!!!!!!! μ! Suncus murinus μ Ω! π μ Ω in vivo! μ μ μ!!! ! in situ! in vivo δ δ !!!!!!!!!! ! in vivo Orexin-Arch Orexin-Arch !!
本組よこ／根間：文１１－０２９＿Ｐ３７７‐４０８
377 378 a b c d 379 p M NH p 380 p 381 a pp b T 382 c S pp p 383 p M M 384 a M b M 385 c M d M e M 386 a M b M a M 387 b M 388 p 389 a b c 390 391 a S H p p b S p 392 a T 393 b S p c S 394 A a b c d 395
O1-1 O1-2 O1-3 O1-4 O1-5 O1-6
O1-1 O1-2 O1-3 O1-4 O1-5 O1-6 O1-7 O1-8 O1-9 O1-10 O1-11 O1-12 O1-13 O1-14 O1-15 O1-16 O1-17 O1-18 O1-19 O1-20 O1-21 O1-22 O1-23 O1-24 O1-25 O1-26 O1-27 O1-28 O1-29 O1-30 O1-31 O1-32 O1-33 O1-34 O1-35
第86回日本感染症学会総会学術集会後抄録（I）
κ κ κ κ κ κ μ μ β β β γ α α β β γ α β α α α γ α β β γ μ β β μ μ α ββ β β β β β β β β β β β β β β β β β β γ β μ μ μ μμ μ μ μ μ β β μ μ μ μ μ μ μ μ μ μ μ μ μ μ β
P.1P.3 P.4P.7 P.8P.12 P.13P.25 P.26P.32 P.33
: : P.1P.3 P.4P.7 P.8P.12 P.13P.25 P.26P.32 P.33 27 26 10 26 10 25 10 0.7% 331 % 26 10 25 10 287,018 280,446 6,572 30,236 32,708 2,472 317,254 313,154 4,100 172,724 168,173 4,551 6,420 6,579 159 179,144
1_alignment.ppt
" " " " n " n n " n " n n n " n n n n " n LGPSSKQTGKGW-SRIWDN! + +! LN-ITKSAGKGAIMRLGDA! " n -------TGKG--------!! -------AGKG--------! " n w w w " n w w " " " 11 12 " n w w w " n w w A! M! O! A!
194621 22 50.06 53.96 90.00 28 87.14 85.00 80.00 75.00 70.00 22 53.96 28 80.75 65.00 60.00 55.00 22 50.06 50.00 Quality of Life !! 281026 281026 -6,500-5,500-4,500-3,500-2,500-1,500-500 500 1,500 2,500-6,401-1,281-3,565-2,154-2,265-2,027-1,869-1,657
1 911 9001030 9:00 A B C D E F G H I J K L M 1A0900 1B0900 1C0900 1D0900 1E0900 1F0900 1G0900 1H0900 1I0900 1J0900 1K0900 1L0900 1M0900 9:15 1A0915 1B0915 1C0915 1D0915 1E0915 1F0915 1G0915 1H0915 1I0915
福岡大学人文論叢47-3
679 pp. 1 680 2 681 pp. 3 682 4 683 5 684 pp. 6 685 7 686 8 687 9 688 pp. b 10 689 11 690 12 691 13 692 pp. 14 693 15 694 a b 16 695 a b 17 696 a 18 697 B 19 698 A B B B A B B A A 20 699 pp. 21 700 pp.
A(6, 13) B(1, 1) 65 y C 2 A(2, 1) B( 3, 2) C 66 x + 2y 1 = 0 2 A(1, 1) B(3, 0) P 67 3 A(3, 3) B(1, 2) C(4, 0) (1) ABC G (2) 3 A B C P 6
1 1 1.1 64 A6, 1) B1, 1) 65 C A, 1) B, ) C 66 + 1 = 0 A1, 1) B, 0) P 67 A, ) B1, ) C4, 0) 1) ABC G ) A B C P 64 A 1, 1) B, ) AB AB = 1) + 1) A 1, 1) 1 B, ) 1 65 66 65 C0, k) 66 1 p, p) 1 1 A B AB A 67
™·”õ/sec3_p63_84/fiü“eflÅ
Section3 64 1 65 Section 3 1 2 3 4 5 6 7 8 9 10 11 12 13 14 1 Babara E. Ainsworth et al. Med. Sci. Sports. Exevc.1993 66 67 Section 3 1 10 9 8 1 2 3 4 7 6 5 6 7 5 1 2 3 4 68 69 Section 3 2 70 Section 3
漸化式のすべてのパターンを解説しましたー高校数学の達人・河見賢司のサイト
https://www.hmg-gen.com/tuusin.html https://www.hmg-gen.com/tuusin1.html 1 2 OK 3 4 {a n } (1) a 1 = 1, a n+1 a n = 2 (2) a 1 = 3, a n+1 a n = 2n a n a n+1 a n = ( ) a n+1 a n = ( ) a n+1 a n {a n } 1,
linearal1.dvi
19 4 30 I 1 1 11 1 12 2 13 3 131 3 132 4 133 5 134 6 14 7 2 9 21 9 211 9 212 10 213 13 214 14 22 15 221 15 222 16 223 17 224 20 3 21 31 21 32 21 33 22 34 23 341 23 342 24 343 27 344 29 35 31 351 31 352
(1) (2) (1) (2) 2 3 {a n } a 2 + a 4 + a a n S n S n = n = S n
. 99 () 0 0 0 () 0 00 0 350 300 () 5 0 () 3 {a n } a + a 4 + a 6 + + a 40 30 53 47 77 95 30 83 4 n S n S n = n = S n 303 9 k d 9 45 k =, d = 99 a d n a n d n a n = a + (n )d a n a n S n S n = n(a + a n
狂牛病調査第２巻1章，２章.doc
21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 2.1 A LD50/30mg () 10 ND 1 2.8 ND ND ND 11 ND 2.3 1.0 ND ND 11 ND ND 1.3 1.7 ND 13 ND
2007050781......_.L.O...z.W
a s d f g a s d f g h j k l 0 in vitro in vivo in vitro in vivo in vivo in vivo in vitro Metabolism Metabolism Endocr Endocr Endocrinol Ann NYA cad Sci J clin Endocr Metab
> > <., vs. > x 2 x y = ax 2 + bx + c y = 0 2 ax 2 + bx + c = 0 y = 0 x ( x ) y = ax 2 + bx + c D = b 2 4ac (1) D > 0 x (2) D = 0 x (3
13 2 13.0 2 ( ) ( ) 2 13.1 ( ) ax 2 + bx + c > 0 ( a, b, c ) ( ) 275 > > 2 2 13.3 x 2 x y = ax 2 + bx + c y = 0 2 ax 2 + bx + c = 0 y = 0 x ( x ) y = ax 2 + bx + c D = b 2 4ac (1) D >
第十四改正日本薬局方第二追補
461 3 3 3 5 5 6 6 10 18 19 79 81 101 113 127 133 139 145 147 152 153 156 158 165 3 19 20 21 22 22 23 24 25 26 26 27 28 29 29 30 31 dl 32 dl 33 34 34 36 36 37 38 38 38 39 40 42 42 42 43 44 45 46 46 47 48
(2) ( 61129) 117, ,678 10,000 10,000 6 ( 7530) 149, ,218 10,000 10,000 7 ( 71129) 173, ,100 10,000 10,000 8 ( 8530) 14
16 8 26 MMF 23 25 5 16 7 16 16 8 1 7 16 8 2 16 8 26 16 8 26 P19 (1) 16630 16,999,809,767 55.69 4,499,723,571 14.74 9,024,172,452 29.56 30,523,705,790 100.00 1 (2) 16 6 30 1 1 5 ( 61129) 117,671 117,678
From Evans Application Notes
3 From Evans Application Notes http://www.eaglabs.com From Evans Application Notes http://www.eaglabs.com XPS AES ISS SSIMS ATR-IR 1-10keV µ 1 V() r = kx 2 = 2π µν x mm 1 2 µ= m + m 1 2 1 k ν = OSC 2
76 3 B m n AB P m n AP : PB = m : n A P B P AB m : n m < n n AB Q Q m A B AQ : QB = m : n (m n) m > n m n Q AB m : n A B Q P AB Q AB 3. 3 A(1) B(3) C(
3 3.1 3.1.1 1 1 A P a 1 a P a P P(a) a P(a) a P(a) a a 0 a = a a < 0 a = a a < b a > b A a b a B b B b a b A a 3.1 A() B(5) AB = 5 = 3 A(3) B(1) AB = 3 1 = A(a) B(b) AB AB = b a 3.1 (1) A(6) B(1) () A(
VOL33NO.3/2010 A B A B p-erk1/2 Time (min) 0 1 2 5 10 15 30 60 90 120 Erk1/2 Time (min) 0 1 2 5 10 15 30 60 90 120 p-vasp VASP C D enos/gapdh x-fold vs sham 2.0 1.5 1.0 0.5 * 0 ANP (-) (+) (-)
2009 Aida et al. Caries Res 2006;40 2000 100 % 78.7 88.0 96.6 98.8 98.8 98.8 100.0 100.0 100 75 69.4 50 75.3 74.8 73.3 73.1 73.0 72.4 71.8 71.7 51.7 40.2 69.4 68.8 73.6 25 22.3 32.8 21.9 22.9 22.1
EPSON LP-S7500シリーズ 取扱説明書1 セットアップと使い方編
A B K L N N N N A B A N B N N A B D A B A B N N N N N N N N N N N K A B E C D F G N N N A B N N A A K B C D L E L L K F A B G N C N N C D B K E A B F AC N K G A B C H K D F E B G H K I G H L J
6 2 2 x y x y t P P = P t P = I P P P ( ) ( ) ,, ( ) ( ) cos θ sin θ cos θ sin θ, sin θ cos θ sin θ cos θ y x θ x θ P
6 x x 6.1 t P P = P t P = I P P P 1 0 1 0,, 0 1 0 1 cos θ sin θ cos θ sin θ, sin θ cos θ sin θ cos θ x θ x θ P x P x, P ) = t P x)p ) = t x t P P ) = t x = x, ) 6.1) x = Figure 6.1 Px = x, P=, θ = θ P
1 12 *1 *2 (1991) (1992) (2002) (1991) (1992) (2002) 13 (1991) (1992) (2002) *1 (2003) *2 (1997) 1
2005 1 1991 1996 5 i 1 12 *1 *2 (1991) (1992) (2002) (1991) (1992) (2002) 13 (1991) (1992) (2002) *1 (2003) *2 (1997) 1 2 13 *3 *4 200 1 14 2 250m :64.3km 457mm :76.4km 200 1 548mm 16 9 12 589 13 8 50m
近畿中国四国農業研究センター研究報告 第７号
230 C B A D E 50m 558 0 1km (mg L 1 ) T N NO 2 3 N NH 4 N 2.0 0 (a) 2001 1.5 6 20 21 5 1.0 0.5 0.0 2.0 1.5 1.0 0.5 0.0 14:00 17:00 (b) 2001 7 3 4 20:00 23:00 2:00 (h) 5:00 8:00 11:00 10 0 5 10 15
DPCはやわかり表紙_2014_H1-H4.indd
C O N T E N T S 1 2 3 4 5 6 7 A B AB 15 15 25 2SD 1 1 A B 15 AB 25 2SD 1 1 1 A B 25 2SD 10 10 10 AB 1 1 1 1 A 1 A 1 B1 15 B 2SD 8 9 10 11 12 13 14 15 16 17 18 DPCA DPCA 7 DPCA DPCA 7 DPCA DPCA 7 DPCA DPCA
untitled
... 1-1... 1-2...... 2-1... 2-2... 2-3... 2-4... 2-5... 2-6... 2-7... 2-8... 2-9... 2-10... 2-11... 2-12... 2-13... 2-14... 2-15... 2-16... 2-17... 2-18... 2-19... 2-20... 2-21... 2-22... 2-23... 2-24...
ウェブ23Brev2
23B 23B.1 23B.1.1 23B.1.2 23B.2 23B.2.1 23B.2.2 a b 23B.3 23B.3.1 23B.3.2 23B.4 23B.4.1 23B.4.2 23B.4.3 23B.5 23B.5.1 23B.5.2 23B.6 23B.6.1 a b c Edman d e 23B.6.2 23B.6.3 23B.7 23B.7.1 a b c 23B.7.2 23B.7.3
22 25 34 44 10 12 14 15 11 12 16 18 19 20 21 11 12 22 10 23 24 12 25 11 12 2611 27 11 28 10 12 29 10 30 10 31 32 10 11 12 33 10 11 12 34
22 25 34 44 10 12 14 15 11 12 16 18 19 20 21 11 12 22 10 23 24 12 25 11 12 2611 27 11 28 10 12 29 10 30 10 31 32 10 11 12 33 10 11 12 34 35 10 12 36 10 12 37 10 38 10 11 12 39 10 11 12 40 11 12 41 10 11
1 9 v.0.1 c (2016/10/07) Minoru Suzuki T µ 1 (7.108) f(e ) = 1 e β(e µ) 1 E 1 f(e ) (Bose-Einstein distribution function) *1 (8.1) (9.1)
1 9 v..1 c (216/1/7) Minoru Suzuki 1 1 9.1 9.1.1 T µ 1 (7.18) f(e ) = 1 e β(e µ) 1 E 1 f(e ) (Bose-Einstein distribution function) *1 (8.1) (9.1) E E µ = E f(e ) E µ (9.1) µ (9.2) µ 1 e β(e µ) 1 f(e )
N cos s s cos ψ e e e e 3 3 e e 3 e 3 e
3 3 5 5 5 3 3 7 5 33 5 33 9 5 8 > e > f U f U u u > u ue u e u ue u ue u e u e u u e u u e u N cos s s cos ψ e e e e 3 3 e e 3 e 3 e 3 > A A > A E A f A A f A [ ] f A A e > > A e[ ] > f A E A < < f ; >
本組よこ／本組よこ＿⑨根間＿Ｐ２２９‐２６４
229 230 231 M 232 pp p 233 M M p 234 H p 235 No S p pp p pp 236 p p p p p 237 p p pp 238 p p 239 M p pp 240 M M 241 M 242 p p 243 p 244 NH p p p p p 245 p p p 246 p p p p p 247 pp p pp p 248 249 p M p
_0212_68<5A66><4EBA><79D1>_<6821><4E86><FF08><30C8><30F3><30DC><306A><3057><FF09>.pdf
1 3 1.1.......................... 3 1............................... 3 1.3....................... 5 1.4.......................... 6 1.5........................ 7 8.1......................... 8..............................
zz + 3i(z z) + 5 = 0 + i z + i = z 2i z z z y zz + 3i (z z) + 5 = 0 (z 3i) (z + 3i) = 9 5 = 4 z 3i = 2 (3i) zz i (z z) + 1 = a 2 {
04 zz + iz z) + 5 = 0 + i z + i = z i z z z 970 0 y zz + i z z) + 5 = 0 z i) z + i) = 9 5 = 4 z i = i) zz i z z) + = a {zz + i z z) + 4} a ) zz + a + ) z z) + 4a = 0 4a a = 5 a = x i) i) : c Darumafactory
Activation and Control of Electron-Transfer Reactions by Noncovalent Bond
2 + 4e- + 4 + hν 2 2 1 2 20 J. Am. Chem. oc. Angew. Chem. Int. Ed. umber of Papers 15 10 5 0 1998 1999 2000 2001 2002 2003 Year : J. Am. Chem. oc. (Trost, B. M.; tanford University, UA) 3 π 1/2 k ET =
untitled
5 28 EAR CCLECCN ECCN 1. 2. 3. 4. 5.EAR page 1 of 28 WWW.Agilent.co.jp -> Q&A ECCN 10020A 10070A 10070B 10070C 10071A 10071B 10072A 10073A 10073B 10073C 10074A 10074B 10074C 10076A 10229A 10240B 10430A
Microsoft Word - 4NMR2.doc
4 NMR 4.1 Zeeman 1, 13 C, 19 F, 31 P NMR 1 13 C 1/2 4.1 7%&'- 89:;'
(e ) (µ ) (τ ) ( (ν e,e ) e- (ν µ,µ ) µ- (ν τ,τ ) τ- ) ( ) ( ) ( ) (SU(2) ) (W +,Z 0,W ) * 1) [ ] [ ] [ ] ν e ν µ ν τ e µ τ, e R,µ R,τ R (2.1a
![(e ) (µ ) (τ ) ( (ν e,e ) e- (ν µ,µ ) µ- (ν τ,τ ) τ- ) ( ) ( ) ( ) (SU(2) ) (W +,Z 0,W ) * 1) [ ] [ ] [ ] ν e ν µ ν τ e µ τ, e R,µ R,τ R (2.1a](/thumbs/100/144882653.jpg "(e ) (µ ) (τ ) ( (ν e,e ) e- (ν µ,µ ) µ- (ν τ,τ ) τ- ) ( ) ( ) ( ) (SU(2) ) (W +,Z 0,W ) * 1) [ ] [ ] [ ] ν e ν µ ν τ e µ τ, e R,µ R,τ R (2.1a")
1 2 2.1 (e ) (µ ) (τ ) ( (ν e,e ) e- (ν µ,µ ) µ- (ν τ,τ ) τ- ) ( ) ( ) ( ) (SU(2) ) (W +,Z 0,W ) * 1) [ ] [ ] [ ] ν e ν µ ν τ e µ τ, e R,µ R,τ R (2.1a) L ( ) ) * 2) W Z 1/2 ( - ) d u + e + ν e 1 1 0 0
n 2 + π2 6 x [10 n x] x = lim n 10 n n 10 k x 1.1. a 1, a 2,, a n, (a n ) n=1 {a n } n=1 1.2 ( ). {a n } n=1 Q ε > 0 N N m, n N a m
![n 2 + π2 6 x [10 n x] x = lim n 10 n n 10 k x 1.1. a 1, a 2,, a n, (a n ) n=1 {a n } n=1 1.2 ( ). {a n } n=1 Q ε > 0 N N m, n N a m](/thumbs/94/118912662.jpg "n 2 + π2 6 x [10 n x] x = lim n 10 n n 10 k x 1.1. a 1, a 2,, a n, (a n ) n=1 {a n } n=1 1.2 ( ). {a n } n=1 Q ε > 0 N N m, n N a m")
1 1 1 + 1 4 + + 1 n 2 + π2 6 x [10 n x] x = lim n 10 n n 10 k x 1.1. a 1, a 2,, a n, (a n ) n=1 {a n } n=1 1.2 ( ). {a n } n=1 Q ε > 0 N N m, n N a m a n < ε 1 1. ε = 10 1 N m, n N a m a n < ε = 10 1 N
.J.[.v/01..
1 J.L. Tan, et al., Proc. Nat l. Acad. Sci. U.S.A. 100, 42003Christopher S. Chen, The Johns Hopkins University 11 12 13 2 14 Box 11 Box 12 11 4 1 14 15 7 6 50 Å 2 0.2 µm 5 25 nm 3 1 4 35Å 10 µm 0.5 µm